Related Experiment Video
Updated: Jul 5, 2026
Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
β-Arrestin and receptor tyrosine kinases in non-small cell lung cancer: A comprehensive review
Rima Paul1, Dhiman Chandra Paul2
1Faculty of Paramedical Sciences, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, PIN - 781026, India.
Background:
Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 80-85% of cases. Most patients are diagnosed at advanced stages, where curative treatment is no longer feasible. Current treatment options, including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, often result in limited efficacy and significant side effects. Chemotherapy regimens, in particular, have reached a therapeutic plateau, necessitating the development of more effective and tolerable therapeutic approaches.
Objectives:
This review aims to explore the roles of β-arrestin and receptor tyrosine kinases (RTKs) in NSCLC progression and treatment. It further investigates the potential of targeted therapies, including those derived from natural compounds, to overcome the limitations of conventional treatment.
Methods:
A systematic review of 25 to 50 research articles was conducted. Peer-reviewed studies were selected from reputable journals, focusing on molecular mechanisms, therapeutic targets, and clinical relevance of β-arrestin and RTK signaling in NSCLC. Articles involving natural compounds with anticancer activity were also included to evaluate their therapeutic promise.
Results:
The review identifies β-arrestin and RTKs as crucial players in NSCLC progression, metastasis, and treatment resistance. Emerging targeted therapies that modulate these molecules show promise in enhancing treatment efficacy and minimizing adverse effects. While natural substances have shown strong anticancer potential in preclinical models, limited clinical data restricts their current use in practice.
Conclusions:
Targeted therapies focusing on β-arrestin and RTK signaling pathways offer a promising alternative to conventional NSCLC treatments. Incorporating natural compounds may further enhance therapeutic outcomes, but more clinical evidence is needed to validate their effectiveness. Continued research into these molecular targets could lead to the development of safer and more efficient NSCLC therapies.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:03Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
Published on: March 10, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:26Receptor Tyrosine Kinases
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...